Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Skeletal muscle wasting occurs in a great majority of cancer patients with advanced disease and is associated with a poor prognosis and decreased survival. Myostatin functions as a negative regulator of skeletal muscle mass and has recently become a therapeutic target for reducing the loss of skeletal muscle and strength associated with clinical myopathies. We generated neutralizing antibodies to myostatin to test their potential use as therapeutic agents to attenuate the skeletal muscle wasting due to cancer. We show that our neutralizing antimyostatin antibodies significantly increase body weight, skeletal muscle mass, and strength in non–tumor-bearing mice with a concomitant increase in mean myofiber area. The administration of these neutralizing antibodies in two preclinical models of cancer-induced muscle wasting (C26 colon adenocarcinoma and PC3 prostate carcinoma) resulted in a significant attenuation of the loss of muscle mass and strength with no effect on tumor growth. We also show that the skeletal muscle mass– and strength-preserving effect of the antibodies is not affected by the coadministration of gemcitabine, a common chemotherapeutic agent, in both non–tumor-bearing mice and mice bearing C26 tumors. In addition, we show that myostatin neutralization with these antibodies results in the preservation of skeletal muscle mass following reduced caloric intake, a common comorbidity associated with advanced cancer. Our findings support the use of neutralizing antimyostatin antibodies as potential therapeutics for cancer-induced muscle wasting. Mol Cancer Ther; 14(7); 1661–70. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826 · cited 1×
“Myostatin was identified as a negative regulator of skeletal muscle mass from the muscle hyperplastic phenotype of naturally occurring hypomorphs and knockout mice (5-7).”
BackgroundDodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319 · cited 1×
“There are no approved drugs for this condition and current therapies are aimed at stimulating appetite or supplementing nutrients in an effort to prevent intake deficits and stabilize weight loss (3).”
BackgroundWeiss, E. P., Racette, S. B., Villareal, D. T., Fontana, L., Steger-May, K., Schechtman, K. B., Klein, S., Ehsani, A. A., Holloszy, J. O., & Washington University School of Medicine CALERIE Group (2007) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00853.2006 · Cited by 218 · cited 1×
“Caloric restriction has been shown to induce the loss of skeletal muscle tissue in elderly men and women (22).”
BackgroundNutritional interventions for cancer-induced cachexia
Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2011.01.001 · Cited by 114 · cited 1×
“Reduced caloric intake is another key component of cancer cachexia and opposing this is part of the current strategy to treat cachexia in cancer patients through administration of appetite stimulants and nutritional support (34).”
BackgroundAntibody-Directed Myostatin Inhibition Enhances Muscle Mass and Function in Tumor-Bearing Mice
Murphy, K. T., Chee, A., Gleeson, B. G., Naim, T., Swiderski, K., Koopman, R., & Lynch, G. S. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00121.2011 · Cited by 111 · cited 2×
“Although antibody-mediated myostatin inhibition has been shown to reduce skeletal muscle loss in several noncancer preclinical models of muscle wasting (13–15), only one previous report describes inhibition in a model of cancer cachexia (16).”
BackgroundResult
Cited by
AgRP Neurons Control Systemic Insulin Sensitivity via Myostatin Expression in Brown Adipose Tissue
Steculorum, S. M., Ruud, J., Karakasilioti, I., Backes, H., Engström Ruud, L., Timper, K., Hess, M. E., Tsaousidou, E., Mauer, J., Vogt, M. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.044 · Cited by 277
The role of exercise-induced myokines in regulating metabolism
Huh, J. Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0994-y · Cited by 242
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., Walgren, R. A., & Stemmer, S. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12331 · Cited by 109
Self-citationMyostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Metadata
- Authors
- Smith, R. C., Cramer, M. S., Mitchell, P. J., Capen, A., Huber, L., Wang, R., Myers, L., Jones, B. E., Eastwood, B. J., Ballard, D., Hanson, J., Credille, K. M., Wroblewski, V. J., Lin, B. K., & Heuer, J. G.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2015-07-01
- Volume
- 14
- Issue
- 7
- Pages
- 1661-1670
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2157550266
- Cited by
- 37
- References
- 6
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0681
- The paper
- Smith, R. C., Cramer, M. S., Mitchell, P. J., Capen, A., Huber, L., Wang, R., Myers, L., Jones, B. E., Eastwood, B. J., Ballard, D., Hanson, J., Credille, K. M., Wroblewski, V. J., Lin, B. K., & Heuer, J. G. (2015). Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.